Literature DB >> 10423140

Many different papillomaviruses have low transcriptional activity in spite of strong epithelial specific enhancers.

G Sailaja, R M Watts, H U Bernard.   

Abstract

Transcription of the E6-E7 genes of human papillomavirus type 11 (HPV-11), HPV-16 and HPV-18 is specific to epithelial cells. This mechanism originates from synergism between different transcription factors such as AP-1, NFI and Sp1, which occur in many different cell types, but whose activity is biased in favour of epithelial cells. In this study, the transcriptional regulation of 14 different papillomavirus types in the absence of the viral E2 transcription factor was compared. Genital HPV types, including high-risk, low-risk and common wart-associated HPVs, were found to have strong epithelial specific enhancers, irrespective of mucosal or skin target cell and pathology. Skin specific non-genital HPVs, like HPV-1 and HPV-8, as well as bovine papillomavirus type 4 (BPV-4), had much lower enhancer activity. Contiguous genomic segments including the enhancer and the E6 promoter of genital as well as non-genital papillomaviruses generally had very low transcriptional activities, presumably due to silencers between enhancer and promoter sequences. This generalization applies to all cell types tested in spite of significant quantitative differences between the cervical carcinoma-derived cell line HeLa, the skin-derived cell line HaCat, undifferentiated and differentiated primary keratinocytes. The only enhancer with activity in fibroblasts was identified in BPV-1, apparently a reflection of the broader target cell specificity of this virus. The low transcriptional activity of papillomaviruses most likely reflects the low gene expression required during most or even all parts of the life-cycle of these viruses.

Entities:  

Mesh:

Year:  1999        PMID: 10423140     DOI: 10.1099/0022-1317-80-7-1715

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  The differentiation-specific factor CDP/Cut represses transcription and replication of human papillomaviruses through a conserved silencing element.

Authors:  M J O'Connor; W Stünkel; C H Koh; H Zimmermann; H U Bernard
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA.

Authors:  W Stünkel; Z Huang; S H Tan; M J O'Connor; H U Bernard
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  The upstream regulatory region of human papillomavirus type 31 is insensitive to glucocorticoid induction.

Authors:  Jennifer L Bromberg-White; Craig Meyers
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Mapping of betapapillomavirus human papillomavirus 5 transcription and characterization of viral-genome replication function.

Authors:  Eve Sankovski; Andres Männik; Jelizaveta Geimanen; Ene Ustav; Mart Ustav
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

5.  Evolutionary variation of papillomavirus E2 protein and E2 binding sites.

Authors:  Adam Rogers; Mackenzie Waltke; Peter C Angeletti
Journal:  Virol J       Date:  2011-08-01       Impact factor: 4.099

6.  Transcriptional activation of the human papillomavirus type 5 and 16 long control region in cells from cutaneous and mucosal origin.

Authors:  Nitesh Mistry; Monika Simonsson; Magnus Evander
Journal:  Virol J       Date:  2007-03-12       Impact factor: 4.099

7.  Characterization and whole genome analysis of human papillomavirus type 16 e1-1374^63nt variants.

Authors:  Ivan Sabol; Mihaela Matovina; Ali Si-Mohamed; Magdalena Grce
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

8.  Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer.

Authors:  Edgar Grinstein; Peter Wernet; Peter J F Snijders; Frank Rösl; Inge Weinert; Wentao Jia; Regine Kraft; Christiane Schewe; Michael Schwabe; Steffen Hauptmann; Manfred Dietel; Chris J L M Meijer; Hans-Dieter Royer
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.